sysa1801
cspc pharmaceuticals,elevation oncology
['sysa1801', 'solid tumor']
first-in-human dose escalation and expansion study of sysa1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors. #asco23 #clinicaltrials #cancerresearch 